Preferred Label : phthalazines;

MeSH definition : Bicyclic heterocyclic compounds containing a BENZENE ring fused to PYRIDAZINE.;

Wikipedia link : https://en.wikipedia.org/wiki/Phthalazines;

Is substance : O;

Details


Main resources

You can consult :

Bicyclic heterocyclic compounds containing a BENZENE ring fused to PYRIDAZINE.

https://www.has-sante.fr/jcms/p_3264984/fr/lynparza-olaparib-prostate
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
metastatic castration resistant prostate cancer
neoplasm metastasis
prostatic neoplasms, Castration-Resistant
antineoplastic agents
olaparib
olaparib
prostatic neoplasms, Castration-Resistant
mutation
genes, BRCA1
genes, BRCA2
phthalazines
piperazines

---
https://www.has-sante.fr/jcms/p_3264802/fr/lynparza-olaparib-ovaire
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
olaparib
administration, oral
antineoplastic agents
antineoplastic combined chemotherapy protocols
Bevacizumab/Olaparib Regimen
ovarian neoplasms
fallopian tube neoplasms
carcinoma
Advanced Primary Peritoneal Carcinoma
advanced primary peritoneal cancer
adult
Homologous Recombination Deficiency
phthalazines
piperazines

---
https://www.has-sante.fr/jcms/p_3241358/fr/lynparza-cancer-de-la-prostate-metastatique-resistant-a-la-castration
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
Poly(ADP-ribose) Polymerase Inhibitors
olaparib
administration, oral
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
adult
BRCA1 Gene Mutation
BRCA2 Gene Mutation
evaluation of the transparency committee
olaparib
phthalazines
piperazines

---
https://www.has-sante.fr/jcms/p_3245412/fr/talzenna
2021
false
false
false
France
administration, oral
talazoparib
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
breast neoplasms
evaluation of the transparency committee
phthalazines

---
https://ansm.sante.fr/disponibilites-des-produits-de-sante/medicaments/lynparza-50-mg-gelule
2020
false
false
false
France
French
drug information
product recalls and withdrawals
olaparib
olaparib
antineoplastic agents
Carcinoma, Ovarian Epithelial
Serous Tubal Intraepithelial Carcinoma
Primary Peritoneal Carcinoma
fallopian tube neoplasms
peritoneal neoplasms
phthalazines
piperazines

---
https://www.ansm.sante.fr/actualites/lynparza-dans-les-cancers-gynecologiques-un-document-pour-guider-les-patientes-lors-du-passage-des-gelules-aux-comprimes
2020
false
false
false
France
French
patients guideline
guidelines for drug use
olaparib
Poly(ADP-ribose) Polymerase Inhibitors
administration, oral
genital neoplasms, female
olaparib
capsules
tablets
phthalazines
piperazines

---
https://www.has-sante.fr/jcms/p_3135598/fr/lynparza
2019
false
false
false
France
olaparib
treatment outcome
insurance, health, reimbursement
administration, oral
Carcinoma, Ovarian Epithelial
antineoplastic agents
evaluation of the transparency committee
olaparib
phthalazines
piperazines

---
https://www.has-sante.fr/jcms/p_3135574/fr/lynparza
2019
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
olaparib
olaparib
administration, oral
breast neoplasms
mutation
genes, BRCA1
genes, BRCA2
breast neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
phthalazines
piperazines

---
https://www.has-sante.fr/jcms/p_3135577/fr/talzenna
2019
false
false
false
France
French
administration, oral
insurance, health, reimbursement
treatment outcome
talazoparib
talazoparib
breast neoplasms
breast neoplasms
genes, BRCA1
genes, BRCA2
mutation
Poly(ADP-ribose) Polymerase Inhibitors
evaluation of the transparency committee
phthalazines

---
https://ansm.sante.fr/uploads/2020/10/19/20201019-lettre-hcp-pui-atuc-lynparza.pdf
2019
false
false
false
France
French
pharmacovigilance note
medication errors
tablets
capsules
olaparib
patient education handout
phthalazines
piperazines

---
https://www.ansm.sante.fr/actualites/nouvelle-mesure-dacces-a-linnovation-atu-de-cohorte-dextension-dindication-pour-lutilisation-de-lynparza-100-mg-et-150-mg-comprimes-olaparib-dans-certains-cancers-gynecologiques
2019
false
false
false
France
French
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
olaparib
olaparib
drug information
antineoplastic agents
advanced primary peritoneal cancer
carcinoma
Maintenance Therapy
phthalazines
piperazines

---
https://www.has-sante.fr/portail/jcms/c_2893483/fr/lynparza
2019
false
false
false
France
French
olaparib
olaparib
evaluation of the transparency committee
phthalazines
piperazines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
talazoparib
talazoparib
breast neoplasms
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
administration, oral
product surveillance, postmarketing
adult
genes, BRCA1
genes, BRCA2
mutation
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
phthalazines
phthalazines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=69043954
2016
false
false
false
France
French
summary of product characteristics
package leaflet
drug combinations
administration, intranasal
nasal sprays
histamine H1 antagonists, non-sedating
anti-inflammatory agents
Fluticasone Propionate
azelastine hydrochloride
fluticasone, combinations
rhinitis, allergic, seasonal
rhinitis, allergic, perennial
drug interactions
pregnancy
breast feeding
Fluticasone Propionate
azelastine hydrochloride
drug evaluation, preclinical
anti-inflammatory agents
histamine H1 antagonists, non-sedating
anti-allergic agents
anti-allergic agents
Fluticasone
suspension, nos
azelastine
propionate
azelastine hydrochloride
nose, nos
Fluticasone Propionate
propionates
suspensions
azelastine hydrochloride
Fluticasone
azelastine
Fluticasone
azelastine
phthalazines
phthalazines
phthalazines

---
http://www.has-sante.fr/portail/jcms/c_2038097/fr/lynparza
http://www.has-sante.fr/portail/jcms/c_2038097/fr/lynparza-olaparib-inhibiteur-de-l-enzyme-parp
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
olaparib
olaparib
treatment outcome
insurance, health, reimbursement
olaparib
adult
ovarian neoplasms
neoplasm recurrence, local
fallopian tube neoplasms
peritoneal neoplasms
enzyme inhibitors
enzyme inhibitors
antineoplastic agents
antineoplastic agents
Poly(ADP-ribose) polymerases
BRCA2 Gene Mutation
BRCA1 Gene Mutation
genes, BRCA1
genes, BRCA2
disease-free survival
Progression-Free survival
mutation
guidelines for drug use
phthalazines
piperazines
phthalazines
piperazines

---
https://www.ema.europa.eu/medicines/human/EPAR/Lynparza
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
olaparib
olaparib
drug approval
europe
antineoplastic agents
antineoplastic agents
enzyme inhibitors
enzyme inhibitors
orphan drug production
adult
ovarian neoplasms
maintenance chemotherapy
Advanced Malignant Neoplasm
ovarian neoplasms
mutation
genes, BRCA1
genes, BRCA2
Recurrent Ovarian Carcinoma
neoplasm recurrence, local
fallopian tube neoplasms
Malignant Peritoneal Neoplasm
administration, oral
peritoneal neoplasms
Poly(ADP-ribose) polymerases
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
contraception
PARP1 protein, human
PARP2 protein, human
PARP3 protein, human
drug evaluation, preclinical
olaparib
cell cycle proteins
phthalazines
piperazines
phthalazines
piperazines

---
http://www.has-sante.fr/portail/jcms/c_1725332/fr/dymista
2014
false
true
false
France
French
drug combinations
azelastine hydrochloride
azelastine hydrochloride
administration, intranasal
nasal sprays
rhinitis, allergic, seasonal
histamine H1 antagonists, non-sedating
histamine H1 antagonists, non-sedating
anti-allergic agents
anti-allergic agents
fluticasone, combinations
anti-inflammatory agents
anti-inflammatory agents
adult
adolescent
treatment outcome
child
guidelines for drug use
evaluation of the transparency committee
rhinitis, allergic, perennial
corticosteroid therapy
Fluticasone Propionate
Fluticasone Propionate
azelastine
azelastine
phthalazines
phthalazines
Fluticasone
Fluticasone

---
Summary Basis of Decision (SBD) for Dymista
137 mcg azelastine hydrochloride and 50 mcg fluticasone propionate per metered spray, suspension for nasal spray, intranasal
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00184
2014
false
false
false
Canada
French
English
drug combinations
azelastine hydrochloride
azelastine hydrochloride
administration, intranasal
nasal sprays
rhinitis, allergic, seasonal
histamine H1 antagonists, non-sedating
histamine H1 antagonists, non-sedating
anti-allergic agents
anti-allergic agents
fluticasone, combinations
anti-inflammatory agents
anti-inflammatory agents
drug approval
canada
adult
adolescent
drug evaluation
risk assessment
treatment outcome
corticosteroid therapy
Fluticasone Propionate
Fluticasone Propionate
drug information
azelastine
azelastine
phthalazines
phthalazines
Fluticasone
Fluticasone

---
Nous contacter.
20/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.